Diakonos Oncology Corporation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Diakonos Oncology Corporation sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Diakonos Oncology Corporation: 3 sponsored US clinical trials, 3 recruiting.
Diakonos Oncology Corporation sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pancreatic Adenosquamous Carcinoma, with 1 trials.
Upper-quartile sponsor footprint
Diakonos Oncology Corporation sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
NCT06805305
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
NCT04157127
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Diakonos Oncology Corporation pipeline
3 recruiting of 3 indexed (100% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Pancreatic Adenosquamous Carcinoma (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Diakonos Oncology Corporation: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Diakonos Oncology Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Diakonos Oncology Corporation page
3 registered trials is a research-attention snapshot, not an endorsement of Diakonos Oncology Corporation or any single study.
- 3 of Diakonos Oncology Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pancreatic Adenosquamous Carcinoma is the condition Diakonos Oncology Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreatic Adenosquamous Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Diakonos Oncology Corporation pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.